Group 1 - MSCI announced the results of the November index review, with adjustments effective after the market close on November 24 [1] - A total of 22 stocks were added to the MSCI Global Small Cap Index, including companies such as Genscript Biotech (01672) and Youzan (08083) [1] - 17 stocks were removed from the MSCI Global Small Cap Index, including China Gold International (02099) and Longi Green Energy (601869) [1] Group 2 - The MSCI Hong Kong Index included 7 new stocks, such as Chow Sang Sang (00116) and MGM China (02282) [2] - The MSCI Hong Kong Index removed stocks like Kintor Pharmaceutical (02171) and HKT Trust (00215) [2][3]

Group 1 - The article provides a list of companies scheduled for various corporate events on November 6, 2025, including shareholder meetings and earnings announcements [1][4]. - Companies mentioned include major players such as Jiesheng Electronics, Xiaoma Zhixing-W, and Wenyuan Zhixing-W, indicating a busy day for the Hong Kong stock market [5]. - The article highlights the significance of these events for investors, as they may impact stock performance and market sentiment [5]. Group 2 - Specific events listed include earnings announcements, dividend distributions, and stock rights issues for companies like Meilan Airport and Huasheng Holdings [5]. - The presence of multiple companies from various sectors suggests a diverse range of investment opportunities on that date [5]. - The article emphasizes the importance of monitoring these events for potential investment strategies and market movements [5].

美高梅中国(02282)发布公告，于2025年11月5日，该公司斥资102.73万港元回购6.64万股股份，每股回 购价格为15.42-15.5港元。 ...

智通财经APP讯，美高梅中国(02282)发布公告，于2025年11月5日，该公司斥资102.73万港元回购6.64万 股股份，每股回购价格为15.42-15.5港元。 ...

格隆汇11月5日丨美高梅中国(02282.HK)公告，11月5日耗资102.7万港元回购6.6万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美高梅中國控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期： 2025年11月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02282 | 說明 | 普通股 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美高梅中國控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02282 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 1 HKD | | 10,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 1 HKD | | 10,000,000, ...

Group 1 - Morgan Stanley reports that Macau's gaming revenue is expected to increase by 16% year-on-year in October 2025, outperforming market expectations [1] - The report indicates that MGM China (02282) is likely to outperform the market index in the next 60 days, with a probability exceeding 80% [1] - MGM China's market share increase in October is expected to boost its EBITDA estimates for the fourth quarter [1] Group 2 - Morgan Stanley sets a target price of HKD 18 for MGM China and maintains an "Overweight" rating on the stock [1]

Core Viewpoint - Morgan Stanley's report indicates that Macau's gaming revenue is expected to increase by 16% year-on-year in October 2025, outperforming market expectations, which is likely to positively impact MGM China Holdings Limited's stock performance in the next 60 days, with an estimated probability exceeding 80% [1] Company Summary - MGM China's market share has improved in October, contributing to a positive outlook for its EBITDA estimates for the fourth quarter [1] - Morgan Stanley has set a target price of HKD 18 for MGM China and maintains an "Overweight" rating on the stock [1]

Core Viewpoint - Morgan Stanley's technical research report indicates that Macau's gaming revenue is expected to increase by 16% year-on-year in October 2025, outperforming market expectations, which is likely to positively impact MGM China’s stock performance in the next 60 days with a probability exceeding 80% [1] Group 1: Company Performance - MGM China's market share increase in October is expected to boost its EBITDA estimates for the fourth quarter [1] - Morgan Stanley sets a target price of HKD 18 for MGM China, with a rating of "Overweight" [1]